Rochester-based organization providing aid to Haiti reacts to international travel ban
ROCHESTER, N.Y. (WROC) – The Trump administration has imposed a travel ban on 12 countries, which took effect Monday. The ban is prohibiting those primarily in Africa and the Middle East from entering the U.S. out of concerns of national security and terrorism.
Haiti is among the countries affected. News 8 spoke to the leader of one local organization overseeing mission work there for years.
Dr. Ralph Pennino co-founded Intervol in the late 80s and for more than three decades, the Rochester-based organization has helped to provide countless medical supplies and equipment in developing countries each year.
In 2017, Dr. Pennino helped to create a school in Leogane, Haiti, which is not far from the country's capital of Port-Au-Prince.
'Right now, we've got grades 1 through 9. These are kids that wouldn't have a choice in education otherwise,' said Dr. Pennino.
Regarding the travel ban, Dr. Pennino says the future of volunteerism is unclear. With a population plagued by poverty and violence, he says it only makes matters more complicated.
'Haiti, interestingly enough, has the highest number of volunteers per capita for a population that comes down to try and help Haiti. To be quite honest, there's probably going to be a lot of repair work to do because people are going to be afraid. And I understand. They're not going to go want to go there,' said Dr. Pennino.
Catholic Charities closing certain refugee resettlement programs
While there's no immediate answer as to when the travel ban will lift, Intervol continues to meet with students online for services like medical checkups or educational lessons.
'We'd normally send doctors down that would go to some of the remote villages to do primary care and the surgeons would go to part of the hospital. That part of what we do, I don't know how long it's going to be,' said Dr. Pennino.
Dr. Pennino added for the first time in the Haitian school's history, their ninth graders are about to complete their national exams. He says that has been a positive in the midst of uncertainty.
More information on ways to donate or help support Intervol's cause in Haiti can be found here.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
37 minutes ago
- Yahoo
UnitedHealth Group received multiple bids for Latin American operations
-- UnitedHealth Group (NYSE:UNH) is considering several offers for its Latin American operations, according to a Reuters report on Monday. The move comes as the largest U.S. health insurer faces challenges that include the departure of its CEO and an alleged criminal accounting investigation. The insurer has been attempting to leave Latin America since 2022, with the sale of its Banmedica subsidiary becoming more urgent in recent months due to increasing pressures on multiple fronts, the report said. So far, UnitedHealth has reportedly received four preliminary bids for Banmedica, which operates in Colombia and Chile, with an estimated value of about $1 billion. In May, UnitedHealth's shares dropped 25.5%, and the year-to-date decline stands at 40%. The company withdrew from Brazil in 2023 and from Peru in March 2025. It aims to secure around $1 billion for Banmedica's operations in Colombia and Chile. The company anticipates setting a deadline for final proposals as early as July. The bids reportedly include offers from Washington, D.C.-based private equity firm Acon Investments, Sao Paulo-based private equity firm Patria Investments, Texas non-profit health organization Christus Health, and Lima-based healthcare and insurance provider Auna. The report mentioned that Auna is currently in discussions with a financial partner. Related articles UnitedHealth Group received multiple bids for Latin American operations Tesla shares slip after double downgrade amid Trump feud fallout What are the three big things in markets now? RBC weighs in
Yahoo
42 minutes ago
- Yahoo
New travel ban sparks concerns among immigrants in metro Atlanta
The Brief The expanded travel ban affects citizens from 19 countries, with Eritrea and Somalia facing full bans, impacting immigrant communities in metro Atlanta. The ban does not cancel existing visas but denies entry to citizens from affected countries without a visa, raising concerns about family separations and community fear. Eritrea's inclusion in the ban is due to high visa overstay rates, a rationale not used in previous bans, highlighting issues with asylum claims and legal immigration processes. CLARKSTON, Ga. - The Trump administration's latest travel ban is now in effect, impacting citizens from 19 countries across the Caribbean, Africa, the Middle East, South America, and Central Asia. While some countries face partial restrictions, others, including Eritrea and Somalia, are under a full ban. SEE ALSO: Trump announces travel ban on a dozen countries: Here's what to know Local perspective The order does not cancel previously issued visas, but citizens from the affected countries who do not already have a visa will be denied entry into the United States. The White House has defended the move as a national security measure, but critics say it is sowing fear and uncertainty in immigrant communities—especially in metro Atlanta, which is home to significant populations from several of the banned nations. What they're saying Omar Shekhey, executive director of the Somali American Community Center in Clarkston and a Somali immigrant himself, recalled the last time Somalia was included on the travel ban list. "Families were separated, people were trying to see grandchildren graduate and could not make it. It was depressing," he said. Now, with Somalia once again under a full travel ban—this time designated as a "terrorist safe haven"—Shekhey said his organization is urging caution. "I'm afraid. We are advising our community not to travel anywhere," he said. "You want to see your mom, you're not coming back." Immigration attorney Jack Kuck agrees with Shekhey's advice. He spent the day fielding calls from concerned families seeking guidance. Eritrea, a country not included in previous travel bans, has now been added to the list. Federal authorities cited high visa overstay rates, particularly among students, as a key reason. "The theory was not used in the last travel ban," Kuck said. "They looked at the most egregious overstay rates for countries and said you can't come in for any reason." He added that visa overstays are often linked to asylum claims, which are legal under U.S. immigration law. Despite the administration's stated rationale, Shekhey believes the ban unfairly targets Somali Americans and separates them from their families. "Every person has a root, a connection. You can't leave your family," he said. "I tell you one thing—we condemn any act of violence." The Source FOX 5's Kevyn Stewart spoke with Omar Shekhey, executive director of the Somali American Community Center in Clarkston, for this article.
Yahoo
43 minutes ago
- Yahoo
RenaissThera Achieves Discovery Milestone in Its Oral Obesity Drug Program
BENGALURU, India, June 09, 2025 (GLOBE NEWSWIRE) -- RenaissThera Private Limited ('RenaissThera'), a Bengaluru-based biotechnology company, announced a major milestone in its obesity drug discovery program targeting the glucose-dependent insulinotropic polypeptide receptor (GIPR). GIPR, an incretin receptor, is a validated target for peptide-based parenteral therapies where both stimulation and inhibition has shown efficacy in treating obesity and its co-morbidities. RenaissThera is developing novel, oral small molecules, both agonists and antagonists, as a more affordable and convenient alternative aiming to expand access for underserved populations in the global obesity market projected to reach USD 38 billion by 2032. Oral small molecules are more economical to manufacture and distribute than peptide-based obesity drugs. These molecules were designed and screened using proprietary AI and ML based platforms, followed by demonstrating in-vitro activity in cell lines and in-vivo activity to impact GIPR in mice to yield 'Hits'. RenaissThera now is advancing these Hits to the Lead optimization program to select candidates for pre-IND studies. RenaissThera is filing 'Composition of Matter' and utility patents for these oral novel small molecule GIPR modulators and continues to expand its innovation portfolio targeting GIP, GLP-1, and apelin receptors in obesity and diabetes. Its AI-powered Innovation Platform, integrating GenAI and machine learning tools, is accelerating the design and optimization of novel small molecules. 'We are grateful to our investors and collaborators for supporting us in reaching this milestone. Our team is focused on pushing candidates toward IND-readiness next year and we are in active discussions with potential pharma partners and investors interested in our obesity program,' said Meena, MD, CEO of RenaissThera. RenaissThera's progress was enabled through its collaboration with VedTechBio Research Private Limited which enabled access to its Agentic AI platform RxAgentAI and discovery expertise. 'We are very pleased with the outcomes of our collaboration with RenaissThera. This milestone further validates our platform and capabilities across key therapeutic areas including obesity, Type 2 diabetes, oncology, and inflammation,' said VedTechBio's Managing Director Sudhir Nagarajan. About RenaissThera RenaissThera is a Bengaluru-based biotech company developing affordable, AI-powered novel small-molecule therapies for high-unmet-need diseases like obesity and diabetes. Its goal is to innovate for underserved populations and expand global access to novel therapies. It leverages India's CRO ecosystem for early-stage R&D to deliver globally relevant innovation. For more information Please contact: Media: Lakshmi Ramakrishna lramakrishna@ Investor & Partnership: Ramkesh Meena bd@
